CMB International Global Markets  Equity Research  Company Update
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
China Healthcare Sector
Jill Wu CFA
Benchen Huang CFA
Mkt Cap (RMB mn)
Avg 3 mths to (RMB mn)
52w HighLow (RMB)
Total Issued A-shares (mn)
Total Issued H-shares (mn)
Source Bloomberg
Shareholding Structure
Ge Li and concerted parties
A-share public shareholders
H-share public shareholders
Source Company
Source Bloomberg
12-mth Price Performance
Source Bloomberg
Auditor Deloitte
Raised full-year guidance post strong
quarterly results - 11 Nov 2021
Strong recovery continued - 16 Aug
Stronger-than-expected growth in Q1
- 20 Apr 2021
Building cutting-edge expertise to
secure long-term growth  1 Apr 2021
SHSZ300 (rebased)
BUY (Maintain)
(Previous TP
RMB16738)
UpDownside
 2021 earnings in line WuXi AppTec reported 2021 revenue of RMB22902
Earnings were in line with our forecasts Gross profit margin (GPM) declined
to 363% in 2021 from 380% in 2020 due to RMB appreciation while adjusted
Non-IFRS GPM at constant exchange rate increased to 403% in 2021 from
380% in 2020 The Company has implemented effective hedging program to
mitigate unfavorable foreign exchange fluctuations considering that majority
of its revenue is denominated in non-RMB currencies By segment revenue
revenue driver for the Company WuXi AppTec maintains its overall revenue
growth guidance of 65-70% YoY for 2022E based on a 100% YoY expected
revenue growth in WuXi Chemistry segment
 Growth in chemical CDMO business to further accelerate in 2022E WuXi
AppTecs CDMO pipeline contained 1666 projects as of Dec 2021 (vs 1314
as of Dec 2020) The rich pipeline provides as a strong long-term growth driver
for CDMO business Revenue from oligo and peptide experienced a 145%
YoY growth and accounted for about 94% of the total CDMO revenue in 2021
The Company expects faster growth from these new modalities in 2022 With
multiple domestic and US manufacturing sites under construction WuXi
AppTec aims to invest RMB9-10bn in Capex in 2022E (vs RMB69bn in 2021)
and 60% of the Capex will go to chemical CDMO business WuXi AppTec is
well positioned to benefit from the surging global demand in manufacturing of
small molecule anti-COVID drugs in our view
 Cell  gene therapy (CGT) CTDMO segment to rebound in 2022 with
smooth project progress CGT CTDMO revenue slightly dropped by 28%
YoY in 2021 due to clients BLA delays and COVID-19 pandemic in US which
was partially offset by a strong 87% YoY growth in China Management
expects the US pipeline projects to advance smoothly in 2022 and sees newly-
launched Shanghai Lingang site to offer better end-to-end services to global
clients which will significantly boost revenue growth of CGT CTDMO segment
 Maintain BUY We raise our TP from RMB16738 to RMB18864 based on a
9-year DCF model (WACC 974% terminal growth rate 30%) We forecast
grow 63%19%32% YoY in FY22E23E24E
(YE 31 Dec)
Revenue (RMB mn)
YoY growth (%)
Consensus EPS (RMB)
Net gearing (%)
Source Company data Bloomberg CMBIGM estimates
WuXi AppTec (603259 CH)
Stronger growth momentum
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 Earnings revision
EPS (US cents)
Source Company data CMBIGM estimates
Figure 2 CMBIGM estimates vs consensus
EPS (US cents)
Source Company data CMBIGM estimates
Figure 3 Valuation on risk-adjusted DCF valuation
DCF Valuation (in Rmb mn)
EBIT(1-tax rate)
- Change in working capital
Target Debt to Asset ratio
Effective Corporate Tax Rate
Terminal value (RMB mn)
Total PV (RMB mn)
Net debt (RMB mn)
Equity value (RMB mn)
 of shares (mn)
Price per share (RMB per share)
Source CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
FY20A FY21A FY22E FY23E FY24E  YE 31 Dec (RMB mn)
FY19A FY20A FY21E FY22E FY23E
8247 11133  Change in working capital
4634  Investment loss (gain)
2619  Other operating activities
1489  Net cash fr operating act
8310 14588 17204 22591  Acquisition of subsidiaries
Other investing activities
(140)  Net cash fr investing act
Selling  distribution exp
Administrative expenses
(1839) (2203) (3473) (4023) (5153)  Net proceeds from shares issued 13162
RD expenses
(942) (1737) (2057) (2696)  Net borrowings
9919 13283  Acquisition of non-controlling interests
Dividends and interests paid
Finance costs net
26  Other financing activities
1400  Net cash fr financing act
Net gain from fair value changes
Pre-tax profit
9933 11935 16083  FX changes
(880) (1490) (1790) (2413)  Cash at beginning of the year
(103)  Cash at the end of the year 10228
YE 31 Dec (RMB mn)
FY20A FY21A FY22E FY23E FY24E  YE 31 Dec
FY20A FY21A FY22E FY23E FY24E
Non-current assets
Other non-current assets
6638  Profit  loss ratios (%)
8394 10988  Gross margin
Trade and bills receivables
8267 10835  EBITDA margin
Prepayments deposits and other receivables
642  Pre-tax margin
2532  Net margin
2261  Balance sheet ratios
Trade and other payables
7731  Current ratio (x)
Other current liabilities
8792  Trade receivables turnover days
Trade payables turnover days
Non-current liabilities
3385  Net debt to total equity ratio (%)
Net cash Net cash Net cash Net cash Net cash
Other non-current liabilities
3385  Returns (%)
Shareholders equity
BVPS (RMB)
Source Company data CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities
or issuer that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities
in this report
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities
and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue
of this report (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve
covered in this report
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIGM
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Global Markets Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Global Markets Limited (CMBIGM) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned
subsidiary of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors  CMBIGM does
not provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives financial position or special
requirements  Past performance has no indication of future performance and actual events may differ materially from that which is contained in the report  The value
of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets
to consult with a professional financial advisor in order to make their own investment decisions
This report or any information contained herein have been prepared by the CMBIGM solely for the purpose of supplying information to the clients of CMBIGM or its
affiliate(s) to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or
enter into any transaction  Neither CMBIGM nor any of its affiliates shareholders agents consultants directors officers or employees shall be liable for any loss
damage or expense whatsoever whether direct or consequential incurred in relying on the information contained in this report  Anyone making use of the information
contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable CMBIGM
advices and forecasts on an AS IS basis  The information and contents are subject to change without notice CMBIGM may issue other publications having information
this report As a result recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume
any responsibility in respect thereof This report is for the use of intended recipients only and this publication may not be reproduced reprinted sold redistributed or
published in whole or in part for any purpose without prior written consent of CMBIGM
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended
from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies Unincorporated Associations etc) of the Order and
may not be provided to any other person without the prior written consent of CMBIGM
For recipients of this document in the United States
CMBIGM is not a registered broker-dealer in the United States  As a result CMBIGM is not subject to US rules regarding the preparation of research reports and the
independence of research analysts  The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research
analyst with the Financial Industry Regulatory Authority (FINRA)  The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the
analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report This report is intended for distribution in the United States
solely to major US institutional investors as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 as amended and may not be furnished to any other
person in the United States Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not
distribute or provide this report to any other person Any US recipient of this report wishing to effect any transaction to buy or sell securities based on the information
provided in this report should do so only through a US-registered broker-dealer
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser as defined in the
Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute reports produced by its respective foreign
entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations Where the report is distributed
in Singapore to a person who is not an Accredited Investor Expert Investor or an Institutional Investor as defined in the Securities and Futures Act (Cap 289) of
Singapore CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law Singapore recipients should contact
CMBISG at 65 6350 4400 for matters arising from or in connection with the report